1. Home
  2. NATH vs ENGN Comparison

NATH vs ENGN Comparison

Compare NATH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nathan's Famous Inc.

NATH

Nathan's Famous Inc.

HOLD

Current Price

$96.58

Market Cap

397.6M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$8.57

Market Cap

379.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NATH
ENGN
Founded
1916
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
397.6M
379.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NATH
ENGN
Price
$96.58
$8.57
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$22.71
AVG Volume (30 Days)
53.0K
331.3K
Earning Date
02-05-2026
12-19-2025
Dividend Yield
2.04%
N/A
EPS Growth
4.02
N/A
EPS
5.56
N/A
Revenue
$154,991,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.66
N/A
Revenue Growth
7.82
N/A
52 Week Low
$75.15
$2.65
52 Week High
$118.50
$11.14

Technical Indicators

Market Signals
Indicator
NATH
ENGN
Relative Strength Index (RSI) 51.14 56.36
Support Level $93.82 $7.57
Resistance Level $99.07 $8.47
Average True Range (ATR) 3.21 0.64
MACD 1.07 -0.00
Stochastic Oscillator 76.07 63.69

Price Performance

Historical Comparison
NATH
ENGN

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: